VRDN — Viridian Therapeutics, Inc.\DE
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on VRDN
| date | signal | measured base rate |
|---|---|---|
| 2026-08-11 | Equal highs taken out structure | -0.70% over 21 days · t = -8.28 · n = 68,636 statistically distinguishable from its control group |
| 2026-08-05 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-07-17 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-06-29 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-02 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-05-05 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-08-19 | Tousignant Jennifer Chief Legal Officer | Open-market sale | 10.0K | 24.50 | 245.0K |
| 2026-08-19 | Tousignant Jennifer Chief Legal Officer | Option exercise | 10.0K | 14.41 | 144.1K |
| 2026-08-19 | Tousignant Jennifer Chief Legal Officer | Open-market sale | 4.2K | 24.50 | 103.2K |
| 2026-08-14 | Tripuraneni Radhika Chief Medical Officer | Option exercise | 40.0K | 13.21 | 528.4K |
| 2026-05-11 | Fairmount Funds Management LLC Director | Open-market purchase | 1.2M | 17.00 | 20.0M |
| 2026-05-11 | Fairmount Healthcare Fund II GP LLC Director | Open-market purchase | 1.2M | 17.00 | 20.0M |
| 2026-05-11 | Fairmount Healthcare Fund II L.P. Director | Open-market purchase | 1.2M | 17.00 | 20.0M |
| 2026-03-03 | Mahoney Stephen F. President and CEO | Shares withheld for tax | 7.4K | 30.19 | 223.6K |
| 2026-03-03 | Mahoney Stephen F. President and CEO | Shares withheld for tax | 7.6K | 29.32 | 223.6K |
| 2026-03-03 | Beetham Thomas W. Chief Operating Officer | Shares withheld for tax | 3.0K | 30.19 | 92.0K |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| FMR LLC | 300.8M | 15.4M |
| BlackRock, Inc. | 153.2M | 7.8M |
| Bellevue Group AG | 131.6M | 6.7M |
| STATE STREET CORP | 91.4M | 4.7M |
| VANGUARD CAPITAL MANAGEMENT LLC | 81.5M | 4.2M |
| Fairmount Funds Management LLC | 76.6M | 3.9M |
| Venrock Adviser, LLC | 75.9M | 3.9M |
| Paradigm Biocapital Advisors LP | 61.6M | 3.1M |
| WELLINGTON MANAGEMENT GROUP LLP | 60.2M | 3.1M |
| Kynam Capital Management, LP | 45.8M | 2.3M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| SCHEDULE 13G | 2026-08-20 | — | on EDGAR ↗ |
| 144 | 2026-08-19 | — | on EDGAR ↗ |
| 4 | 2026-08-18 | 2026-08-14 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-07 | — | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Viridian Therapeutics, Inc.\DE (VRDN) filed form SCHEDULE 13G · 2026-08-20 · SEC EDGAR
- Viridian Therapeutics, Inc.\DE (VRDN) filed form 144 · 2026-08-19 · SEC EDGAR
- Viridian Therapeutics, Inc.\DE (VRDN) filed form 4 · 2026-08-18 · SEC EDGAR
Ask the AI about VRDN
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →